Alternative dosage schedules with HPV virus-like particle vaccines

Expert Review of Vaccines

Volumn 13, Issue 8, 2014, Pages 1027-1038

  Stanley, Margaret A ^a   Sudenga, Staci L ^b   Giuliano, Anna R ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Dose schedule; Dosing; HPV vaccination; Immunogenicity; Virus like particle

Indexed keywords

HEPATITIS B VACCINE; VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE;

AGE; ANTIBODY RESPONSE; COMPARATIVE STUDY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; GENDER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; LIVER PROTECTION; LONG TERM CARE; PAPILLOMAVIRUS INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL MATURATION; SEXUALITY; SYSTEMATIC REVIEW; TREATMENT DURATION; VACCINATION; DOSE RESPONSE; IMMUNIZATION; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; PROCEDURES;

DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; IMMUNIZATION; IMMUNIZATION SCHEDULE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84904322244     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.935767     Document Type: Review

References (89)

1. Bernard HU, Burk RD, Chen Z, et al. Classification of papillomaviruses. (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401(1): 70-9
2. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24(Suppl 3):S3/35-41
3. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009;4: 8
4. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011;364(5): 401-11
5. Joura EA, Kjaer SK, Wheeler CM, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008; 26(52): 6844-51
6. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367(9518): 1247-55
7. Arbyn M, Castellsague X, de Sanjose S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22(12): 2675-86
8. Garland SM, Skinner SR, Brotherton JM. Adolescent and young adult HPV vaccination in Australia: achievements and challenges. Prev Med 2011;53(Suppl 1): S29-35
9. Centers for Disease Control. National and state vaccination coverage among adolescents aged 13 through 17 years - United States, 2010. MMWR Morb Mortal Wkly Rep 2011;60: 1117-23
10. Centers for Disease Control. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States. MMWR Morb Mortal Wkly Rep 2013;62(29): 591-5
11. Sudenga SL, Royse KE, Shrestha S. Role and uptake of human papillomavirus vaccine in adolescent health in the United States. Adolesc Health Med Ther 2011; 2011(2): 63-74
12. Siegrist CA. Vaccine immunology. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Saunders-Elsevier; London, UK: 2008
13. Lanzavecchia A, Sallusto F. Human B cell memory. Curr Opin Immunol 2009;21(3): 298-304
14. Rajewsky K. Clonal selection and learning in the antibody system. Nature 1996; 381(6585): 751-8
15. Food US. Drug Administration Vaccines and Related Biological Products Advisory Committee (VRBPAC): VRBPAC background document: Gardasil TM HPV quadrivalent vaccine. In: 2006 VRBPAC Meeting. Available from: www.fda.izov/ohrms/dockets/ac/06/briefing/2006-4222B3
16. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980;303(15): 833-41
17. Van Damme P, Moiseeva A, Marichev I, et al. Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study. BMC Infect Dis 2010;10: 357
18. van der Sande MA, Mendy M, Waight P, et al. Similar long-term vaccine efficacy of two versus three doses of HBV vaccine in early life. Vaccine 2007;25(8): 1509-12
19. Heron LG, Chant KG, Jalaludin BB. A novel hepatitis B vaccination regimen for adolescents: two doses 12 months apart. Vaccine 2002;20(29-30): 3472-6
20. Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003;63(10): 1021-51
21. Middleman AB, Kozinetz CA, Robertson LM, et al. The effect of late doses on the achievement of seroprotection and antibody titer levels with hepatitis b immunization among adolescents. Pediatrics 2001;107(5): 1065-9
22. Chen CC, Chang MH, Lee HC, et al. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in healthy adolescents on two-dose schedule. Acta Paediatr Taiwan 1999;40(3): 157-60
23. WHO. Hepatitis B vaccines: WHO position paper - recommendations. Vaccine 2010;28(3): 589-90
24. Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis 2011;53(1): 68-75
25. Petersen KM, Bulkow LR, McMahon BJ, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J 2004;23(7): 650-5
26. Lin YC, Chang MH, Ni YH, et al. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 2003;187(1): 134-8
27. Goldstein ST, Zhou F, Hadler SC, et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005;34(6): 1329-39
28. Giuliano AR, Lee JH, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011;377(9769): 932-40
29. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with virus-like particles from cotton tail rabbit papillomavirus (CRPV) can protect against experimentally CRPV infection. J Virol 1995;69: 3959-63
30. Suzich JA, Ghim SJ, Palmer Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995;92(25): 11553-7
31. Day PM, Kines RC, Thompson CD, et al. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 2010;8(3): 260-70
32. Carter JJ, Madeleine MM, Shera K, et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res 2001;61(5): 1934-40
33. Lu B, Viscidi RP, Villa LL, et al. Capsid antibody response to genital HPV 6, 11, 16, and 18 infection in healthy men. In: 28th International Papillomavirus Conference; Puerto Rico, USA; 2012
34. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006;24(27): 5571-83
35. Schwarz TF, Spaczynski M, Schneider A, et al. Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years. Hum Vaccin 2011;7(9): 958-65
36. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25(26): 4931-9
37. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009;5(10): 705-19
38. Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011;7(12): 1343-58
39. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13(1): 89-99
40. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009;2(10): 868-78
41. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:c3493
42. Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009;373(9679): 1949-57
43. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365(17): 1576-85
44. Kjaer SK. An evaluation of the long term effectiveness, immunogenicity and safety of Gardasil TM in previously vaccinated women (abstract PS 2-6). Eurogin; 8-10 May 2011; Lisbon, Portugal
45. Roteli-Martins C, Naud P, De Borba P, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012;8(3): 390-7
46. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118(5): 2135-45
47. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007;26(3): 201-9
48. Hillman RJ, Giuliano AR, Palefsky JM, et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol 2012;19(2): 261-7
49. Alexander KA, Giuliano AR. HPV-beyond cervical cancer (online resource center). Am J Med 2012;125(7):S1
50. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40(6): 564-71
51. Stanley M. Immune responses to human papillomavirus. Vaccine 2006;24(Suppl 1): S16-22
52. WHO. Meeting of the WHO Human Papillomavirus Vaccine Advisory Committee, April 2010. Wkly Epidemiol Rec 2011;86(22): 227-31
53. Stanley M, Lowy DR, Frazer I. Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006;24(Suppl 3): S3/106-113
54. Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines -. immune responses. Vaccine 2012;30(Suppl 5): F83-7 • This review discusses the durability of the antibody response and the importance of antibody isotype, affinity and avidity for vaccine effectiveness.
55. Esposito S, Birlutiu V, Jarcuska P, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study. Pediatr Infect Dis J 2011;30(3):e49-55 • This is a randomized controlled trial extending the three-dose vaccine schedule to 12 months.
56. Zimmerman RK, Nowalk MP, Lin CJ, et al. Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women. J Womens Health (Larchmt) 2010; 19(8): 1441-7 • This is a randomized controlled trial extending the three-dose vaccine schedule to 12 months.
57. Randomized trial of alternative HPV vaccination schedules in males in a University setting. Available from: http://clinicaltrials.gov/ct2/show/ NCT01184079
58. Neuzil KM, Canh do G, Thiem VD, et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA 2011;305(14): 1424-31 • This is a randomized controlled trial extending the three-dose vaccine schedule to 12 months.
59. Giuliano AR, Lazcano-Ponce E, Villa LL, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev 2008;17(8): 2036-43
60. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30(Suppl 5):F12-23
61. Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975-2008. National Cancer Institute; Bethesda, MD, USA: 2011
62. Kjaer SK, Hansen BT, Tryggvadottir L, et al. The long-term study of Gardasil in previously vaccinated women: absence of HPV replacement disease. In: 28th International Papillomavirus Conference; Puerto Rico, USA; 2012
63. Rowhani-Rahbar A, Alvarez FB, Bryan JT, et al. Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. J Clin Virol 2012;53(3): 239-43
64. Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011;7(12): 1374-86 •• This is a randomized controlled trial assessing the immunogenicity and/or effectiveness of two versus three doses of the bivalent HPV vaccine in adolescent cohorts.
65. Lazcano-Ponce E, Stanley M, Munoz N, et al. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 2014;32(6): 725-32 •• This is a randomized controlled trial assessing the immunogenicity and/or effectiveness of two versus three doses of the bivalent HPV vaccine in adolescent cohorts.
66. Evaluation of immunogenicity and safety of two 2-dose human papillomavirus (HPV) vaccine schedules in 9-14 year old girls. Available from: www.clinicaltrials.gov/ct2/show/NCT01381575
67. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013;309(17): 1793-802 •• This is a randomized controlled trial assessing the immunogenicity and/or effectiveness of two versus three doses of the quadrivalent HPV vaccine in adolescent cohorts.
68. Sankaranarayanan R. 2 vs 3 doses HPV vaccine schedule: low- and middle-income countries. In: Eurogin Conference; Florence, Italy; 2013 •• This is a randomized controlled trial assessing the immunogenicity and/or effectiveness of two versus three doses of the quadrivalent HPV vaccine in adolescent cohorts.
69. A controlled trial to assess the immunogenicity of a proposed paediatric dosing schedule of human papillomavirus vaccine. Available from: http://clinicaltrials. gov/show/NCT00501137
70. Smolen KK, Gelinas L, Franzen L, et al. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 2012;30(24): 3572-9 • This is a randomized controlled trial assessing B and T cell memory of two versus three doses of the quadrivalent HPV vaccine in adolescent cohorts.
71. Shlomchik MJ, Weisel F. Germinal center selection and the development of memory B and plasma cells. Immunol Rev 2012; 247(1): 52-63
72. Rosado MM, Scarsella M, Pandolfi E, et al. Switched memory B cells maintain specific memory independently of serum antibodies: the hepatitis B example. Eur J Immunol 2011;41(6): 1800-8
73. Dauner JG, Pan Y, Hildesheim A, et al. Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Vaccine 2010;28(33): 5407-13
74. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Can Inst 2011;103(19): 1444-51
75. Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 2013;6(11): 1242-50
76. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24(33-34): 5937-49
77. Palefsky J. Protocol 020 Investigators. Long-term effectiveness, tolerability and immungenicity of quadrivalent HPV vaccine in men. In: Eurogin Conference; Florence, Italy; 2013
78. Rowhani-Rahbar A, Mao C, Hughes JP, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 2009;27(41): 5612-19
79. Longet S, Schiller JT, Bobst M, et al. A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol 2011;85(24): 13253-9
80. Scherpenisse M, Schepp RM, Mollers M, et al. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLoS One 2013;8(9):e74797
81. Boxus M, Lockman L, Fochesato M, et al. Antibody avidity measurements in recipients of Cervarix((R)) vaccine following a two-dose schedule or a three-dose schedule. Vaccine 2014;32(26): 3232-6
82. European Medicines Agency. Assessment report-Cervarix. Procedure No. EMEA/H/C/000721/II/0048. Committee for medicinal products for human use. 2013
83. WHO Strategic Advisory Group of Experts. Evidence based recommendations on human papilloma virus (HPV) vaccines schedules. In: SAGE Meeting; Geneva, Switzertland; 2014
84. Immunogenicity and safety of Glaxosmithkline Biologicals' huma papillomavirus (HPV) vaccine 580299 in healthy females 15-25 years of age. Available from: http://clinicaltrials.gov/ct2/show/NCT00552279
85. Randomized trial of alternative quadrivalent human papilloma virus (HPV) vaccination schedules in a University setting. Available from: http://clinicaltrials.gov/show/NCT00572832
86. Immunogenicity and reactogenicity of alternative schedules of gardasil. Available from: http://clinicaltrials.gov/show/NCT00524745
87. Partially blind study to evaluate immunogenicity & safety of GSK Bio's HPV vaccine 580299 in healthy women aged 9-25 Yrs. Available from: http://clinicaltrials.gov/show/NCT00541970
88. Evaluation of immunogenicity levels in women With HPV vaccine in Mexico. Available from: http://clinicaltrials.gov/show/NCT01717118
89. Trial of two versus three doses of human papillomavirus (HPV) vaccine in India. Available from: http://clinicaltrials.gov/show/NCT00923702